Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study
Acetalax and bisacodyl represent a promising new class of drugs with a distinct mechanism of action, targeting mitochondrial function and suppressing tumor growth in vivo. Their effectiveness, particularly in triple-negative breast cancer (TNBC), may be predicted by TRPM4 expression, though predictive accuracy improves when additional genes are included in a multivariate analysis. Acetalax exhibits a biphasic mean half-life of approximately 5.8 hours.